A groundbreaking study led by Professor Zhou Zhenfeng and his team at Hangzhou Obstetrics and Gynecology Hospital explores the effectiveness of 5:2 Intermittent Fasting (IF) in managing Metabolic-Associated Fatty Liver Disease (MAFLD/MASLD). Published in Frontiers in Nutrition, this randomized controlled trial compared 5:2 IF with traditional daily calorie restriction (DCR) over 12 weeks, using the iLivTouch® Non-Invasive Liver Detection System to assess liver health. The results offer exciting insights into dietary interventions for MAFLD/MASLD patients.
Swipe through the slides below for key details! 👇
Let’s continue to explore innovative approaches to improve liver health and patient outcomes! 💪